PANews reported on March 21 that according to CryptoSlate, the decentralized science (DeSci) project Curetopia has successfully raised $1.77 million through the Bio Protocol Launchpad, aiming to promote the development of drugs for rare diseases with the help of the Solana blockchain. Through blockchain crowdfunding and tokenization mechanisms, the project enables patients and researchers to jointly fund drug development and share ownership of their results. Curetopia recently discovered a candidate drug that is expected to treat AARS2 mitochondrial disease and has applied for a provisional patent. The drug will be on-chain in the form of IP-NFT, and will be further fragmented into tradable IP-Tokens. CURES token holders will directly participate in governance and obtain commercial benefits. The project has reached cooperation with COMBINEDBrain and Unravel Biosciences.
Curetopia was founded by Ethan Perlstein, a Harvard PhD and Y Combinator alumnus who has advanced rare disease treatments to Phase III clinical trials at low cost. The global rare disease market is huge, but has long been ignored by traditional large pharmaceutical companies due to its long commercial return cycle. Curetopia hopes to break this pattern and enable patient communities and researchers to participate in and promote the development of drugs that truly have social value with a lower threshold.
